

CLNE0029: Clinical neuroscience of neurodegenerative diseases

[View Online](#)

1

Clarke C, Howard R, Rossor M, et al., editors. Neurology: a Queen Square textbook. Second edition. Chichester, West Sussex, UK: : Wiley Blackwell 2016.
<https://onlinelibrary.wiley.com/doi/book/10.1002/9781118486160>

2

McCarthy RA, Warrington EK. Cognitive neuropsychology: a clinical introduction. San Diego, California: : Academic Press, Inc 1990.
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618430004761&institutionId=4761&customerId=4760

3

Rossor M, Growdon JH. The dementias 2. [Place of publication not identified]: : Butterworth Heinemann/Elsevier 2007.
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618250004761&institutionId=4761&customerId=4760

4

Hodges JR. Cognitive assessment for clinicians. 3 ed. [Oxford]: : Oxford University Press 2017. <http://dx.doi.org/10.1093/med/9780198749189.001.0001>

5

Kandel ER, Schwartz JH, Jessell TM, et al., editors. Principles of neural science. Fifth edition.

New York: : McGraw Hill Medical 2013.

http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605810004761&institutionId=4761&customerId=4760

6

Husain M. Oxford textbook of cognitive neurology and dementia. [Oxford]: : Oxford University Press 2016.

http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605720004761&institutionId=4761&customerId=4760

7

Alzheimer's Facts and Figures Report | Alzheimer's Association.

<https://www.alz.org/alzheimers-dementia/facts-figures>

8

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine 2016;**8**:595–608. doi:10.15252/emmm.201606210

9

Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet Neurology 2014;**13**:614–29. doi:10.1016/S1474-4422(14)70090-0

10

Loy CT, Schofield PR, Turner AM, et al. Genetics of dementia. The Lancet 2014;**383**:828–40. doi:10.1016/S0140-6736(13)60630-3

11

Karran E, Hardy J. Anti-amyloid Therapy for Alzheimer's Disease — Are We on the Right Road? New England Journal of Medicine 2014;**370**:377–8. doi:10.1056/NEJMe1313943

12

Johnson KA, Fox NC, Sperling RA, et al. Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine 2012;**2**:a006213–a006213.
doi:10.1101/cshperspect.a006213

13

Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology 2014;**10**:204–16.
doi:10.1038/nrneurol.2014.24

14

Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nature Reviews Disease Primers Published Online First: 23 April 2015. doi:10.1038/nrdp.2015.5

15

Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington's disease. The Lancet Neurology 2017;**16**:837–47. doi:10.1016/S1474-4422(17)30280-6

16

Carroll JB, Bates GP, Steffan J, et al. Treating the whole body in Huntington's disease. The Lancet Neurology 2015;**14**:1135–42. doi:10.1016/S1474-4422(15)00177-5

17

Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. The Lancet Neurology 2011;**10**:31–42. doi:10.1016/S1474-4422(10)70276-3

18

Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet Neurology 2012;**11**:42–53. doi:10.1016/S1474-4422(11)70263-0

19

Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *The Lancet Neurology* 2013;**12**:637–49. doi:10.1016/S1474-4422(13)70088-7

20

Jones L, Houlden H, Tabrizi SJ. DNA repair in the trinucleotide repeat disorders. *The Lancet Neurology* 2017;**16**:88–96. doi:10.1016/S1474-4422(16)30350-7

21

Rossor M, Collinge J, Fox N, et al. Dementia and Cognitive Impairment. In: Clarke C, Howard R, Rossor M, et al., eds. *Neurology*. Chichester, UK: : John Wiley & Sons, Ltd 2016. 289–336. doi:10.1002/9781118486160.ch8

22

Rossor MN, Fox NC, Mummery CJ, et al. The diagnosis of young-onset dementia. *The Lancet Neurology* 2010;**9**:793–806. doi:10.1016/S1474-4422(10)70159-9

23

Schott JM, Fox NC, Rossor MN. Assessment and investigation of the cognitively impaired adult. In: Husain M, Schott JM, eds. *Oxford Textbook of Cognitive Neurology and Dementia*. Oxford University Press 2016. 221–30. doi:10.1093/med/9780199655946.003.0021

24

Green AJE. RT-QulC: a new test for sporadic CJD. *Practical Neurology* Published Online First: 3 October 2018. doi:10.1136/practneurol-2018-001935

25

Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases.

Nature 2016;**539**:217–26. doi:10.1038/nature20415

26

Mead S, Rudge P. CJD mimics and chameleons. Practical Neurology 2017;**17**:113–21. doi:10.1136/practneurol-2016-001571

27

Walker Z, Possin KL, Boeve BF, et al. Lewy body dementias. The Lancet 2015;**386**:1683–97. doi:10.1016/S0140-6736(15)00462-6

28

Halliday GM, Holton JL, Revesz T, et al. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica 2011;**122**:187–204. doi:10.1007/s00401-011-0852-9

29

Barker RA, Williams-Gray CH. Review: The spectrum of clinical features seen with alpha synuclein pathology. Neuropathology and Applied Neurobiology 2016;**42**:6–19. doi:10.1111/nan.12303

30

Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics 2014;**23**:6139–46. doi:10.1093/hmg/ddu334

31

McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. Neurology 2017;**89**:88–100. doi:10.1212/WNL.0000000000004058

32

Weil RS, Lashley TL, Bras J, et al. Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. *F1000Research* 2017;**6**. doi:10.12688/f1000research.11725.1

33

Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. *Journal of Neurochemistry* 2016;**138**:6–31. doi:10.1111/jnc.13654

34

Gordon E, Rohrer JD, Fox NC. Advances in neuroimaging in frontotemporal dementia. *Journal of Neurochemistry* 2016;**138**:193–210. doi:10.1111/jnc.13656

35

Ahmed RM, Devenney EM, Irish M, et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. *Journal of Neurology, Neurosurgery & Psychiatry* 2016;**87**:1234–41. doi:10.1136/jnnp-2014-308350

36

Fletcher PD, Warren JD. Semantic Dementia: a specific network-opathy. *Journal of Molecular Neuroscience* 2011;**45**:629–36. doi:10.1007/s12031-011-9586-3

37

Goll JC, Crutch SJ, Loo JHY, et al. Non-verbal sound processing in the primary progressive aphasia. *Brain* 2010;**133**:272–85. doi:10.1093/brain/awp235

38

Goll JC, Ridgway GR, Crutch SJ, et al. Nonverbal sound processing in semantic dementia: A functional MRI study. *NeuroImage* 2012;**61**:170–80. doi:10.1016/j.neuroimage.2012.02.045

39

Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology* 2011;**76**:1006–14.
doi:10.1212/WNL.0b013e31821103e6

40

Grossman M. The non-fluent/agrammatic variant of primary progressive aphasia. *The Lancet Neurology* 2012;**11**:545–55. doi:10.1016/S1474-4422(12)70099-6

41

Leyton CE, Hodges JR, McLean CA, et al. Is the logopenic-variant of primary progressive aphasia a unitary disorder? *Cortex* 2015;**67**:122–33. doi:10.1016/j.cortex.2015.03.011

42

Marshall CR, Hardy CJD, Volkmer A, et al. Primary progressive aphasia: a clinical approach. *Journal of Neurology* 2018;**265**:1474–90. doi:10.1007/s00415-018-8762-6

43

Rohrer JD, Knight WD, Warren JE, et al. Word-finding difficulty: a clinical analysis of the progressive aphasia. *Brain* 2007;**131**:8–38. doi:10.1093/brain/awm251

44

Rohrer JD, Ridgway GR, Crutch SJ, et al. Progressive logopenic/phonological aphasia: Erosion of the language network. *NeuroImage* 2010;**49**:984–93.
doi:10.1016/j.neuroimage.2009.08.002

45

Rohrer JD, Rossor MN, Warren JD. Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. *Neurology* 2010;**75**:603–10.
doi:10.1212/WNL.0b013e3181ed9c6b

46

Rohrer JD, Sauter D, Scott S, et al. Receptive prosody in nonfluent primary progressive aphasia. *Cortex* 2012;**48**:308–16. doi:10.1016/j.cortex.2010.09.004

47

Warren JD, Rohrer JD, Rossor MN. Frontotemporal dementia. *BMJ* 2013;**347**:f4827–f4827. doi:10.1136/bmj.f4827

48

Lynch DS, Rodrigues Brandão de Paiva A, Zhang WJ, et al. Clinical and genetic characterization of leukoencephalopathies in adults. *Brain* 2017;**140**:1204–11. doi:10.1093/brain/awx045

49

Hollak CEM, Lachmann R, editors. Inherited metabolic disease in adults: a clinical guide. [New York]: : Oxford University Press 2016.
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3043210560004761&institutionId=4761&customerId=4760

50

Devenney E, Vucic S, Hodges JR, et al. Motor neuron disease-frontotemporal dementia: a clinical continuum. *Expert Review of Neurotherapeutics* 2015;**15**:509–22. doi:10.1586/14737175.2015.1034108

51

Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration* 2017;**18**:153–74. doi:10.1080/21678421.2016.1267768

52

Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative Disorder Risk in Idiopathic

REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE 2014;**9**.
doi:10.1371/journal.pone.0089741

53

Kielb SA, Ancoli-Israel S, Rebok GW, et al. Cognition in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAS): Current Clinical Knowledge and the Impact of Treatment. NeuroMolecular Medicine 2012;**14**:180–93. doi:10.1007/s12017-012-8182-1

54

Mander BA, Winer JR, Jagust WJ, et al. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? Trends in Neurosciences 2016;**39**:552–66. doi:10.1016/j.tins.2016.05.002

55

McCarter SJ, St. Louis EK, Boeve BF. Sleep Disturbances in Frontotemporal Dementia. Current Neurology and Neuroscience Reports 2016;**16**. doi:10.1007/s11910-016-0680-3

56

Ooms S, Ju Y-E. Treatment of Sleep Disorders in Dementia. Current Treatment Options in Neurology 2016;**18**. doi:10.1007/s11940-016-0424-3

57

Hardy CJD, Marshall CR, Golden HL, et al. Hearing and dementia. Journal of Neurology 2016;**263**:2339–54. doi:10.1007/s00415-016-8208-y

58

Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. The Lancet 2017;**390**:2673–734. doi:10.1016/S0140-6736(17)31363-6

59

Goll JC, Crutch SJ, Warren JD. Central auditory disorders: toward a neuropsychology of auditory objects. *Current Opinion in Neurology* 2010;**23**:617–27.
doi:10.1097/WCO.0b013e32834027f6

60

Husain M. *Oxford textbook of cognitive neurology and dementia*. [Oxford]: : Oxford University Press 2016.
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3119511110004761&institutionId=4761&customerId=4760

61

Blennow K, Hardy J, Zetterberg H. The Neuropathology and Neurobiology of Traumatic Brain Injury. *Neuron* 2012;**76**:886–99. doi:10.1016/j.neuron.2012.11.021

62

Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? *Nature Reviews Neurology* 2013;**9**:211–21.
doi:10.1038/nrneurol.2013.29

63

McKee AC, Stein TD, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. *Brain* 2013;**136**:43–64. doi:10.1093/brain/aws307

64

Fleminger S. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. *Journal of Neurology, Neurosurgery & Psychiatry* 2003;**74**:857–62.
doi:10.1136/jnnp.74.7.857

65

Scott G, Ramlackhansingh AF, Edison P, et al. Amyloid pathology and axonal injury after brain trauma. *Neurology* 2016;**86**:821–8. doi:10.1212/WNL.0000000000002413

66

Hereditary and sporadic beta-amyloidoses.
<https://www.bioscience.org/2013/v18/af/4173/fulltext.htm>

67

Johnson GVW. Tau phosphorylation in neuronal cell function and dysfunction. *Journal of Cell Science* 2004;**117**:5721–9. doi:10.1242/jcs.01558

68

Revesz T, Holton JL, Lashley T, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. *Acta Neuropathologica* 2009;**118**:115–30. doi:10.1007/s00401-009-0501-8

69

Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathologica* 2012;**123**:1–11. doi:10.1007/s00401-011-0910-3

70

Thal DR. Neurodegeneration in Normal Brain Aging and Disease. *Science of Aging Knowledge Environment* 2004;**2004**:pe26–pe26. doi:10.1126/sageke.2004.23.pe26

71

Braak H, Braak E. Staging of alzheimer's disease-related neurofibrillary changes. *Neurobiology of Aging* 1995;**16**:271–8. doi:10.1016/0197-4580(95)00021-6

72

Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991;**41**:479–479. doi:10.1212/WNL.41.4.479

73

Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathologica* 2012;**123**:1-11. doi:10.1007/s00401-011-0910-3

74

Dobson R, Alvares D. The difficulties with vitamin B. *Practical Neurology* 2016;**16**:308-11. doi:10.1136/practneurol-2015-001344

75

Jonathan Carr. Neurosyphilis. *Practical Neurology* 2003;**3**:328-41. <https://pn.bmj.com/content/3/6/328>

76

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. *The Lancet Neurology* 2016;**15**:391-404. doi:10.1016/S1474-4422(15)00401-9

77

Salvarani C, Brown RD, Hunder GG. Adult primary central nervous system vasculitis. *The Lancet* 2012;**380**:767-77. doi:10.1016/S0140-6736(12)60069-5

78

Halperin JJ, Kurlan R, Schwalb JM, et al. Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response. *Neurology* 2015;**85**:2063-71. doi:10.1212/WNL.0000000000002193

79

Arash Asher. The effect of cancer treatment on cognitive function. undefined <https://www.semanticscholar.org/paper/The-effect-of-cancer-treatment-on-cognitive-Asher-Myers/6bdd550dab6cfad0714aa76dd2ee439ad983e4be>

80

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. *The Lancet Neurology* 2016;**15**:391–404. doi:10.1016/S1474-4422(15)00401-9

81

Cognitive Impairment Associated with Cancer: A Brief Review. *Innovations in Clinical Neuroscience* 2018;**15**. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819720/>

82

Haddow LJ, Cartledge JD, Manji H. HIV and the brain: from AIDS to old age. *Clinical Medicine* 2013;**13**:s24–8. doi:10.7861/clinmedicine.13-6-s24

83

Nightingale S, Michael BD, Defres S, et al. Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed. *Practical Neurology* 2013;**13**:354–6. doi:10.1136/practneurol-2013-000689

84

HIV in the United Kingdom 2016 infographic.
<https://www.gov.uk/government/publications/hiv-in-the-united-kingdom>

85

Itzhaki RF, Lathe R, Balin BJ, et al. Microbes and Alzheimer's Disease. *Journal of Alzheimer's Disease* 2016;**51**:979–84. doi:10.3233/JAD-160152

86

Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. *The Lancet Neurology* 2014;**13**:1139–51. doi:10.1016/S1474-4422(14)70137-1

87

Richard W. Price and Bruce J. Brew. The AIDS Dementia Complex. The Journal of Infectious Diseases 1988;**158**
. https://www.jstor.org/stable/30136610?seq=1#metadata_info_tab_contents

88

UK National Guidelines for HIV Testing 2008. <https://www.bhiva.org/HIV-testing-guidelines>

89

Zhou L, Miranda-Saksena M, Saksena NK. Viruses and neurodegeneration. Virology Journal 2013;**10**. doi:10.1186/1743-422X-10-172

90

De Chiara G, Marcocci ME, Sgarbanti R, et al. Infectious Agents and Neurodegeneration. Molecular Neurobiology 2012;**46**:614–38. doi:10.1007/s12035-012-8320-7

91

Wendorf KA, Winter K, Zipprich J, et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clinical Infectious Diseases 2017;**65**:226–32. doi:10.1093/cid/cix302

92

Ghanem KG. REVIEW: Neurosyphilis: A Historical Perspective and Review. CNS Neuroscience & Therapeutics 2010;**16**:e157–68. doi:10.1111/j.1755-5949.2010.00183.x

93

Somasundaram O. Neuro syphilis: Portrayals by Sir Arthur Conan Doyle. Indian Journal of Psychiatry 2009;**51**. doi:10.4103/0019-5545.55103

94

Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. *Stroke* 2006;**37**:2220–41. doi:10.1161/01.STR.0000237236.88823.47

95

Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia. *Stroke* 2011;**42**:2672–713. doi:10.1161/STR.0b013e3182299496

96

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. *The Lancet* 2001;**357**:169–75. doi:10.1016/S0140-6736(00)03589-3

97

Leys D, Hénon H, Mackowiak-Cordoliani M-A, et al. Poststroke dementia. *The Lancet Neurology* 2005;**4**:752–9. doi:10.1016/S1474-4422(05)70221-0

98

O'Brien JT, Thomas A. Vascular dementia. *The Lancet* 2015;**386**:1698–706. doi:10.1016/S0140-6736(15)00463-8